Back to top

Strategic Collaborations and Promising Clinical Developments Drive Buy Rating for Marker Therapeutics

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Marker Therapeutics (MRKR – Research Report), with a ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

MARKER THERAPEUTICS, INC. (MRKR)